Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) Interest Expenses (2019 - 2022)

Keros Therapeutics filings provide 4 years of Interest Expenses readings, the most recent being $1000.0 for Q1 2022.

  • On a quarterly basis, Interest Expenses changed 0.0% to $1000.0 in Q1 2022 year-over-year; TTM through Dec 2022 was $1000.0, a 75.0% decrease, with the full-year FY2022 number at $1000.0, down 75.0% from a year prior.
  • Interest Expenses hit $1000.0 in Q1 2022 for Keros Therapeutics, roughly flat from $1000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $3000.0 in Q3 2019 to a low of $1000.0 in Q2 2020.
  • Median Interest Expenses over the past 4 years was $1000.0 (2020), compared with a mean of $1500.0.
  • The widest YoY moves for Interest Expenses: up 0.0% in 2020, down 50.0% in 2020.
  • Keros Therapeutics' Interest Expenses stood at $3000.0 in 2019, then crashed by 66.67% to $1000.0 in 2020, then changed by 0.0% to $1000.0 in 2021, then changed by 0.0% to $1000.0 in 2022.
  • The last three reported values for Interest Expenses were $1000.0 (Q1 2022), $1000.0 (Q4 2021), and $1000.0 (Q3 2021) per Business Quant data.